Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine
Executive Summary
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.